Cubist Systematic Strategies’s Regeneron Pharmaceuticals REGN Stock Holding History
Bought
Maintained
Sold
| Quarter | Market Value | Status | Shares |
Change in Stake | Trade Value | Portfolio Weight | Portfolio Position | |
|---|---|---|---|---|---|---|---|---|
|
2025
Q3 | $44.6M | Sell |
79,264
-15,678
| -17% | -$8.86M | 0.21% | 90 |
|
|
2025
Q2 | $49.8M | Buy |
+94,942
| New | +$53M | 0.23% | 67 |
|
|
2025
Q1 | – | Sell |
-39,693
| Closed | -$27.3M | – | 3407 |
|
|
2024
Q4 | $28.3M | Buy |
+39,693
| New | +$33.3M | 0.18% | 104 |
|
|
2024
Q1 | – | Sell |
-22,773
| Closed | -$21.7M | – | 4181 |
|
|
2023
Q4 | $20M | Buy |
22,773
+20,065
| +741% | +$16.5M | 0.13% | 162 |
|
|
2023
Q3 | $2.23M | Sell |
2,708
-4,911
| -64% | -$3.86M | 0.02% | 1297 |
|
|
2023
Q2 | $5.47M | Sell |
7,619
-14,871
| -66% | -$11.5M | 0.04% | 788 |
|
|
2023
Q1 | $18.5M | Buy |
22,490
+20,126
| +851% | +$15.2M | 0.11% | 179 |
|
|
2022
Q4 | $1.71M | Buy |
2,364
+666
| +39% | +$491K | 0.01% | 1985 |
|
|
2022
Q3 | $1.17M | Sell |
1,698
-9,027
| -84% | -$5.68M | 0.01% | 2492 |
|
|
2022
Q2 | $6.34M | Buy |
10,725
+10,625
| +10,625% | +$6.91M | 0.04% | 769 |
|
|
2022
Q1 | $70K | Sell |
100
-9,188
| -99% | -$5.81M | ﹤0.01% | 3316 |
|
|
2021
Q4 | $5.87M | Sell |
9,288
-7,594
| -45% | -$4.67M | 0.06% | 545 |
|
|
2021
Q3 | $10.2M | Buy |
16,882
+10,129
| +150% | +$6.29M | 0.13% | 181 |
|
|
2021
Q2 | $3.77M | Sell |
6,753
-7,611
| -53% | -$3.86M | 0.04% | 716 |
|
|
2021
Q1 | $6.8M | Buy |
14,364
+10,206
| +245% | +$4.97M | 0.09% | 299 |
|
|
2020
Q4 | $2.01M | Sell |
4,158
-881
| -17% | -$476K | 0.03% | 936 |
|
|
2020
Q3 | $2.82M | Sell |
5,039
-5,095
| -50% | -$3.09M | 0.04% | 697 |
|
|
2020
Q2 | $6.32M | Buy |
10,134
+4,235
| +72% | +$2.4M | 0.11% | 238 |
|
|
2020
Q1 | $2.88M | Sell |
5,899
-15,907
| -73% | -$6.56M | 0.08% | 338 |
|
|
2019
Q4 | $8.19M | Buy |
21,806
+11,665
| +115% | +$3.92M | 0.15% | 144 |
|
|
2019
Q3 | $2.81M | Sell |
10,141
-12,366
| -55% | -$3.66M | 0.06% | 493 |
|
|
2019
Q2 | $7.04M | Buy |
22,507
+15,941
| +243% | +$5.31M | 0.13% | 195 |
|
|
2019
Q1 | $2.7M | Buy |
6,566
+5,312
| +424% | +$2.19M | 0.09% | 323 |
|
|
2018
Q4 | $468K | Sell |
1,254
-9,446
| -88% | -$3.46M | 0.02% | 1012 |
|
|
2018
Q3 | $4.32M | Buy |
10,700
+10,400
| +3,467% | +$3.96M | 0.24% | 66 |
|
|
2018
Q2 | $103K | Sell |
300
-1,937
| -87% | -$606K | 0.01% | 1529 |
|
|
2018
Q1 | $770K | Sell |
2,237
-9,303
| -81% | -$3.24M | 0.05% | 569 |
|
|
2017
Q4 | $4.34M | Buy |
11,540
+10,965
| +1,907% | +$4.44M | 0.23% | 57 |
|
|
2017
Q3 | $257K | Sell |
575
-96
| -14% | -$45.7K | 0.01% | 1279 |
|
|
2017
Q2 | $330K | Buy |
671
+428
| +176% | +$187K | 0.02% | 970 |
|
|
2017
Q1 | $94K | Sell |
243
-1,728
| -88% | -$641K | 0.01% | 1407 |
|
|
2016
Q4 | $724K | Sell |
1,971
-192
| -9% | -$73K | 0.06% | 489 |
|
|
2016
Q3 | $870K | Sell |
2,163
-4,891
| -69% | -$1.96M | 0.06% | 471 |
|
|
2016
Q2 | $2.46M | Sell |
7,054
-1,715
| -20% | -$660K | 0.14% | 149 |
|
|
2016
Q1 | $3.16M | Sell |
8,769
-6,680
| -43% | -$2.75M | 0.18% | 113 |
|
|
2015
Q4 | $8.39M | Buy |
15,449
+8,757
| +131% | +$4.74M | 0.49% | 13 |
|
|
2015
Q3 | $3.11M | Buy |
+6,692
| New | +$3.59M | 0.16% | 124 |
|
|
2015
Q2 | – | Sell |
-6,249
| Closed | -$2.82M | – | 2008 |
|
|
2015
Q1 | $2.82M | Buy |
6,249
+1,476
| +31% | +$626K | 0.14% | 171 |
|
|
2014
Q4 | $1.96M | Sell |
4,773
-16,059
| -77% | -$6.32M | 0.11% | 252 |
|
|
2014
Q3 | $7.51M | Sell |
20,832
-6,821
| -25% | -$2.29M | 0.46% | 14 |
|
|
2014
Q2 | $7.81M | Buy |
+27,653
| New | +$8.2M | 0.47% | 13 |
|
Other funds holding REGN
Cubist Systematic Strategies's REGN Position: Q3 2025 in Review
Cubist Systematic Strategies reduced its Regeneron Pharmaceuticals (REGN) stake by 17% in Q3 2025, selling an estimated $8.86M and leaving 79,264 shares worth $44.6M. The position accounts for 0.21% of the portfolio, ranked #90.
Cubist Systematic Strategies first reported a position in REGN in Q2 2014 and has held it in 41 quarters since. The position peaked at $49.8M in Q2 2025. 1,244 funds tracked by Wall St. Rank hold REGN as of Q3 2025.
- Cubist Systematic Strategies held 79,264 shares of Regeneron Pharmaceuticals worth $44.6M as of Q3 2025.
- Cubist Systematic Strategies sold 15,678 Regeneron Pharmaceuticals shares in Q3 2025, an estimated $8.86M.
- Regeneron Pharmaceuticals made up 0.21% of Cubist Systematic Strategies's portfolio in Q3 2025, its #90 holding.
- Cubist Systematic Strategies first reported a position in Regeneron Pharmaceuticals in Q2 2014 and has held it in 41 quarters since.
- Cubist Systematic Strategies's Regeneron Pharmaceuticals position peaked at $49.8M in Q2 2025.
- 1,244 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q3 2025.
Based on Cubist Systematic Strategies's 13F filing for Q3 2025, filed 14 Nov 2025.